← Back to Clinical Trials
Recruiting NCT05804578

NCT05804578 Using a Blood Test to Monitor Metastatic Breast Cancer Treatment

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT05804578
Status Recruiting
Phase —
Sponsor Dr. Christopher Mueller
Condition Metastatic Breast Cancer
Study Type OBSERVATIONAL
Enrollment 150 participants
Start Date 2023-10-19
Primary Completion 2026-01

Trial Parameters

Condition Metastatic Breast Cancer
Sponsor Dr. Christopher Mueller
Study Type OBSERVATIONAL
Phase N/A
Enrollment 150
Sex FEMALE
Min Age 18 Years
Max Age N/A
Start Date 2023-10-19
Completion 2026-01

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

The goal of this observational study is to assess the effectiveness of the mDETECT breast cancer blood test at monitoring treatment response in women with metastatic breast cancer undergoing treatment.

Eligibility Criteria

Inclusion Criteria -Adult women (≥ 18 years of age) with proven diagnosis of adenocarcinoma of the breast with evidence of recurrent or metastatic disease not amenable to resection or radiation therapy with curative intent \[to be herein described as 'metastatic'\]

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

VIEW ON CLINICALTRIALS.GOV ↗ MORE METASTATIC BREAST CANCER TRIALS
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology